- Home
- Free App Analytics
- PneumoRecs VaxAdvisor
- PneumoRecs VaxAdvisor Vs. ASCVD Risk Estimator Plus
PneumoRecs VaxAdvisor vs ASCVD Risk Estimator Plus Usage & Stats
This is the PneumoRecs VaxAdvisor App created by the Centers for Disease Control and Prevention (CDC) in collaboration with the Georgia Tech Research Institute. PneumoRecs VaxAdvisor provides patient-specific pneumococcal vaccination guidance consistent with the pneumococcal vaccination recommendations of the Advisory Committee on Immunization Practices. Vaccination providers enter a patient’s age and respond to prompts about the patient’s pneumococcal vaccination history and underlying medical conditions. The app then displays patient-specific pneumococcal vaccination recommendations consistent with the recommended U.S. immunization schedule.
- Apple App Store
- Free
- Medical
Store Rank
- -
The updated ASCVD Risk Estimator Plus uses up to date science and user feedback to help a clinician and patient build a customized risk lowering plan by estimating and monitoring change in 10-year ASCVD risk.
Use the app to:
• Estimate a patient’s initial 10-year ASCVD risk using the pooled cohort equation
• Receive an individualized, risk-based, intervention approach
• Project the impact of specific interventions on a patient’s risk
• Guide clinician-patient discussion around customizing an intervention plan
• Update risk at follow-up based on a patient’s response to therapy using the Million Hearts Longitudinal model
Advice from the app is derived from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, the 2018 ACC/AHA et.al Guideline on the Management of Blood Cholesterol, the 2017 ACC/AHA et.al Guideline on High Blood Pressure in Adults, the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, and the 2016 Million Hearts Longitudinal ASCVD Risk Assessment Tool user guide. The information and recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.
- Apple App Store
- Free
- Medical
Store Rank
- -
PneumoRecs VaxAdvisor vs. ASCVD Risk Estimator Plus ranking comparison
Compare PneumoRecs VaxAdvisor ranking trend in the past 28 days vs. ASCVD Risk Estimator Plus
Rank
No Data Available
PneumoRecs VaxAdvisor vs. ASCVD Risk Estimator Plus ranking by country comparison
Compare PneumoRecs VaxAdvisor ranking trend in the past 28 days vs. ASCVD Risk Estimator Plus
All categories
No Data Available
Medical
Compare to any site with our free trial
PneumoRecs VaxAdvisor VS.
ASCVD Risk Estimator Plus
January 17, 2025